Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Awareness and interest in genomic SNP testing for prostate cancer risk

From: Interest in genomic SNP testing for prostate cancer risk: a pilot survey

Item PRAP group Urology group p
N (%) N (%)
Awareness    
Awareness of genomic SNP testing for PC risk    0.38
  Not aware 28 (70.0) 34 (85.0)  
  A little 4 (10.0) 1 (2.5)  
  Somewhat 4 (10.0) 3 (7.5)  
  Quite 2 (5.0) 2 (5.0)  
  Very aware 2 (5.0) 0 (0.0)  
Awareness of genomic SNP tests on the Internet    
  Not aware 40 (100.0) 38 (95.0) 0.49
  Missing 0 (0.0) 2 (5.0)  
Interest    
Interest in genomic SNP testing if standard-of-care    <0.001
  Strongly disagree 0 (0.0) 6 (15.0)  
  Sort of disagree 0 (0.0) 6 (15.0)  
  Neither agree nor disagree 0 (0.0) 4 (10.0)  
  Sort of agree 10 (25.0) 10 (25.0)  
  Strongly agree 30 (75.0) 14 (35.0)  
Interest change if ancestry markers revealed    0.58
  No change 20 (50.0) 17 (42.5)  
  Maybe more interest 12 (30.0) 17 (42.5)  
  Definitely more interest 8 (20.0) 6 (15.0)  
  1. Bold: Results significant (p < 0.05).